Radioactive microspheres aimed at prostate cancer: early safety trial underway

NCT ID NCT06192758

Ongoing Disease control Sponsor: Boston Scientific Corporation Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 31, 2026 · Updated 2 times

Summary

This early study tests the safety of TheraSphere PCa, tiny radioactive glass beads injected into the prostate to treat localized prostate cancer. The trial involves 36 men with favorable intermediate-risk cancer and aims to find the maximum safe radiation dose. Researchers will monitor side effects and adverse events over 90 days.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Yttrium-90 Glass Microspheres (TheraSphere PCa)
What this could lead to: If successful, this could offer a new, less invasive treatment option for localized prostate cancer using targeted radiation.
What could go wrong: This is an early feasibility study with only 36 participants, focused on safety and dosing. It is too small and early to know if it will be effective or widely applicable.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer chromosome 2q32-q33 deletion syndrome neoplasm prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER PROSTATE

Contacts and locations

Locations

Northwestern Memorial Hospital

Chicago, Illinois, 60611, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.